Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2013; 19(48): 9377-9382
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9377
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9377
Table 2 Maternal outcomes in the control group and tenofovir disoproxil fumarate-treated group n (%)
| Maternal outcomes | Control group (n= 24) | Treated group (n= 21) |
| HBV DNA < 50 IU/mL | 0 (0) | 13 (62) |
| Normalized ALT (U/L) | 15 (61) | 17 (82) |
| Elevated creatinine kinase (> 165 mg/dL) | 0 (0) | 1 (4.7) |
| Spontaneous abortion | 1 (4) | 0 (0) |
| Gestational diabetes | 0 (0) | 1 (4.7) |
| Vaginitis | 0 (0) | 1 (4.7) |
| Arrhythmia | 0 (0) | 1 (4.7) |
| Anemia | 0 (0) | 1 (4.7) |
| Proteinuria | 1 (4.2) | 2 (10) |
- Citation: Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, Gulsun S, Barcin T, Kalkanli S, Dal MS, Ayaz C. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013; 19(48): 9377-9382
- URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9377.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9377